Present and evolving role of eptifibatide in the treatment of acute coronary syndromes

Expert Review of Cardiovascular Therapy

Volumn 5, Issue 3, 2007, Pages 401-412

  Tricoci, Pierluigi ^a   Newby, L Kristin ^b   Kandzari, David E ^b   Harrington, Robert A ^b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Coronary artery disease; Myocardial infarction; Platelets; Thrombosis; Unstable angina

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATINE KINASE MB; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; PLACEBO; TICLOPIDINE; TIROFIBAN; TROPONIN I; TROPONIN T;

ACUTE CORONARY SYNDROME; BLEEDING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG CLEARANCE; DRUG COST; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; META ANALYSIS; MONOTHERAPY; MUSCLE NECROSIS; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; RECEPTOR BINDING; REVIEW; ST SEGMENT ELEVATION; SYSTEMATIC REVIEW; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; TREATMENT OUTCOME; UNITED STATES;

ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CLINICAL TRIALS; DRUG COSTS; HUMANS; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 34249291927     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.5.3.401     Document Type: Review

References (57)

1. Braunwald E. Unstable angina: an etiologic approach to management. Circulation 98(21), 2219-2222 (1998).
2. Harker LA. Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Am. J. Cardiol. 60(3), 20B-28B (1987).
3. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/ IIIa with eptifibatide in patients with acute coronary syndromes. N. Engl. J. Med. 339(7), 436-443 (1998).
4. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N. Engl. J. Med. 338(21), 1498-1505 (1998).
5. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N. Engl. J. Med. 338(21), 1488-1497 (1998).
6. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation 105(3), 316-321 (2002).
7. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 357(9272), 1915-1924 (2001).
8. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N. Engl. J. Med. 330(14), 956-961 (1994).
9. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 349(9063), 1429-1435 (1997).
10. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N. Engl. J. Med. 336(24), 1689-1696 (1997).
11. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 352(9122), 87-92 (1998).
12. Scarborough RM. Development of eptifibatide. Am. Heart J. 138(6 Pt 1), 1093-1104 (1999).
13. Harrington RA, Kleiman NS, Kottke-Marchant K et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am. J. Cardiol. 76(17), 1222-1227 (1995).
14. Schror K, Weber AA. Comparative pharmacology of GP IIb/IIIa antagonists. J. Thromb. Thrombolysis 15(2), 71-80 (2003).
15. Tcheng JE, Talley JD, O'Shea JC et al. Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). Am. J. Cardiol. 88(10), 1097-1102 (2001).
16. Phillips DR, Teng W, Arfsten A et al. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 96(5), 1488-1494 (1997).
17. Tardiff BE, Jennings LK, Harrington RA et al. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT. Circulation 104(4), 399-405 (2001).
18. Gilchrist IC, O'Shea JC, Kosoglou T et al. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation 104(4), 406-411 (2001).
19. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 356(9247), 2037-2044 (2000).
20. Giugliano RP, Newby LK, Harrington RA et al. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome - study design and rationale. Am. Heart J. 149(6), 994-1002 (2005).
21. Gretler DD. Pharmacokinetic and pharmacodynamic properties of eptifabatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin. Clin. Ther. 25(10), 2564-2574 (2003).
22. Gretler DD, Guerciolini R, Williams PJ. Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function. Clin. Ther. 26(3), 390-398 (2004).
23. Batchelor WB, Tolleson TR, Huang Y et al. Randomized comparison of platelet inhibition with abciximab, tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation 106(12), 1470-1476 (2002).
24. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 96(5), 1445-1453 (1997).
25. Danzi GB, Capuano C, Sesana M, Mauri L, Sozzi FB. Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention. Am. J. Cardiol. 97(4), 489-493 (2006).
26. Dalby M, Montalescot G, Bal dit Sollier C et al. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. J. Am. Coll. Cardiol. 43(2), 162-168 (2004).
27. Kastrati A, Mehilli J, Schuhlen H et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N. Engl. J. Med. 350(3), 232-238 (2004).
28. Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of platelets (CLEAR PLATELETS) study. Circulation 111(9), 1153-1159 (2005).
29. Kleiman NS, Lincoff AM, Flaker GC et al. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. Circulation 101(7), 751-757 (2000).
30. Boersma E, Harrington RA, Moliterno DJ et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359(9302), 189-198 (2002).
31. Roffi M, Chew DP, Mukherjee D et al. Platelet glycoprotein IIb/ IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. Eur. Heart J. 23(18), 1441-1448 (2002).
32. Marso SP, Bhatt DL, Roe MT et al. Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. Circulation 102(24), 2952-2958 (2000).
33. Dyke CM, Bhatia D, Lorenz TJ et al. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Ann. Thorac. Surg. 70(3), 866-871 (2000).
34. Greenbaum AB, Harrington RA, Hudson MP et al. Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. J. Am. Coll. Cardiol. 37(2), 492-498 (2001).
35. Lauer MA, Houghtaling PL, Peterson JG et al. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation 104(23), 2772-2777 (2001).
36. Braunwald E, Antman EM, Beasley JW et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J. Am. Coll. Cardiol. 40(7), 1366-1374 (2002).
37. Roffi M, Chew DP, Mukherjee D et al. Platelet glycoprotein IIb/ IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 104(23), 2767-2771 (2001).
38. Mark DB, Harrington RA, Lincoff AM et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation 101(4), 366-371 (2000).
39. Brown RE, Henderson RA, Koster D, Hutton J, Simoons ML. Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in Unstable angina: Receptor Suppression Using Integrilin Therapy. Eur. Heart J. 23(1), 50-58 (2002).
40. Brown R, Armstrong P. Cost effectiveness in Canada of eptifibatide treatment for acute coronary syndrome patients using PURSUIT subgroup analysis. Can. J. Cardiol. 19(2), 161-166 (2003).
41. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 349(9063), 1422-1428 (1997).
42. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial. Am. Heart J. 141(3), 402-409 (2001).
43. Schweiger MJ, Changezi HU, Naglieri-Prescod D, Cook JR. Open-label, sequential comparison of eptifibatide with abciximab for patients undergoing percutaneous coronary intervention. Clin. Ther. 25(1), 225-234 (2003).
44. Suleiman M, Gruberg L, Hammerman H et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention. J. Invasive Cardiol. 15(6), 319-323 (2003).
45. Bittl JA, Strony J, Brinker JA et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N. Engl. J. Med. 333(12), 764-769 (1995).
46. Lincoff AM, Bittl JA, Harrington RA et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289(7), 853-863 (2003).
47. Gibson CM, Morrow DA, Murphy SA et al. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. J. Am. Coll. Cardiol. 47(12), 2364-2373 (2006).
48. Stone GW, McLaurin BT, Cox DA et al. Bivalirudin for patients with acute coronary syndromes. N. Engl. J. Med. 355(21), 2203-2216 (2006).
49. The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N. Engl. J. Med. 354(14), 1464-1476 (2006).
50. Stone GW, Bertrand ME, Moses JW et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA 297(6), 591-602 (2007).
51. Rao SV, O'Grady K, Pieper KS et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am. J. Cardiol. 96(9), 1200-1206 (2005).
52. Rao SV, Jollis JG, Harrington RA et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 292(13), 1555-1562 (2004).
53. Alexander KP, Chen AY, Roe MT et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294(24), 3108-3116 (2005).
54. Alexander KP, Chen AY, Newby LK et al. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines) initiative. Circulation 114(13), 1380-1387 (2006).
55. Kirtane AJ, Piazza G, Murphy SA et al. Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. J. Am. Coll. Cardiol. 47(12), 2374-2379 (2006).
56. Kastrati A, Mehilli J, Neumann F-J et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 295(13), 1531-1538 (2006).
57. Newby LK, Ohman EM, Christenson RH et al. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. Circulation 103(24), 2891-2896 (2001).